Navigation Links
Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
Date:10/22/2007

tests of ventilation and perfusion that require administration of radioactive isotopes and not always readily available. Early results of our investigations indicate no significant differences in values calculated with traditional radiospirometric studies and VRI, a simpler, office-based, non-invasive, and radiation-free alternative," said Dr. Rodolfo Morice, MD, at The University of Texas MD Anderson Cancer Center USA.

"The VRI system allows you to monitor and record breath sounds. This non- invasive technique has the potential to diagnose a variety of airway conditions promptly and in a cost effective manner," said Prof. Atul Mehta, Medical Director Lung Transplantation, Vice Chairman and Head of Bronchology Pulmonary, Allergy and Critical Care Medicine Cleveland Clinic, Ohio USA.

The availability of the VRIxp(TM) system in the US, advances our efforts to create a new clinical paradigm in which our technology will be the standard application in a broad line of clinical applications," said Igal Kushnir, President & CEO of Deep Breeze Ltd. "It also represents a significant development in the concerted push by Deep Breeze Ltd. to build a global marketing and sales platform directed at pulmonary medical care. Indeed, the potential for this medical technology to effectively help managing patients is unlimited."

About VRIxp(TM)

The procedure takes only minutes in a physician's office and may be performed repeatedly for continuous monitoring. Results are delivered to the physician immediately and can be stored in a system database for future use. The radiation-free technology has been used in more than 3,500 patients worldwide without any single adverse event.

About Deep Breeze Ltd.

Founded in 2001, Israel-based Deep Breeze Ltd. (http://www.deepbreeze.com) is a privately-held medical device company that is providing advanced pulmonary imaging with its proprietary patented technolog
'/>"/>

SOURCE Deep Breeze Ltd.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Breathing Exercises help cardiac patients to breeze through surgery
2. Glaxo launches pills to help smokers quit in 7-12 weeks
3. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
4. Dr Reddy’s Laboratories launches Hyalosy
5. Serum Institute Launches New Tetanus-Diphtheria Vaccine
6. Scottish Health Minister Launches Organ Donor Plan
7. GlaxoSmithKline launches diabetes and cancer drugs
8. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
9. Pfizer Launches Viagra For Lung Disease In UK
10. PM Launches Healthcare Foundation For India
11. African Union Launches A Programme On Acceleration of HIV Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 1Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 1Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 3Nostrils Compete to Relay Key Fragrance 54963 1Nostrils Compete to Relay Key Fragrance 54963 2